Now live: Pro — the full 13F research suite for serious investorsSee pricing →
CAXTON CORP

Q4 2023 · 13F-HR

CAXTON CORPholdings as filed

Filed 2024-02-14 · accession 0000919574-24-001188

$18.5M
Reported value
12
Positions
2023-12-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
98422E103XERSXERIS BIOPHARMA HOLDINGS INC$13.3M71.6%5,641,920CommonSOLE
805111101SVRASAVARA INC$1.7M8.97%353,441CommonSOLE
76200L309RZLTREZOLUTE INC$1.3M7.07%1,318,967CommonSOLE
78462F103SPYSPDR S&P 500 ETF TR$628,1443.39%1,322CommonSOLE
608550208MTEMEURMOLECULAR TEMPLATES INC$510,5102.76%136,866CommonSOLE
084670702BRK/BBERKSHIRE HATHAWAY INC DEL$369,2931.99%1,035CommonSOLE
03770N101APGEAPOGEE THERAPEUTICS INC$205,4361.11%7,353CommonSOLE
00370M103ABVXABIVAX SA$179,1490.97%16,743CommonSOLE
52886X107LXEOLEXEO THERAPEUTICS INC$138,4760.75%10,319CommonSOLE
41358P205HARPUSDHARPOON THERAPEUTICS INC$129,2910.70%13,176CommonSOLE
20454B104CMPXCOMPASS THERAPEUTICS INC$67,8060.37%43,465CommonSOLE
01671P100ALLKGUSDALLAKOS INC$67,4570.36%24,710CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.